Fig. 4
Neutralizing antibody ELISA titers across study groups measured 30 days post-vaccination boost (dpv). Box plots illustrate the distribution and variability of ELISA titers within each group, indicating the degree of immune response elicited by each vaccination regimen. Groups A and F, which received a combined BCG and SCV2 vaccine, demonstrated the highest median titers (approaching 1.25), suggesting strong immunogenicity. Group A exhibited a wider range of responses, reflecting greater variability among individuals. In contrast, Groups C (BCG-only), B (control), D, and E showed markedly lower titers, with medians closer to 0.25, indicating weaker or minimal immune responses. These findings underscore the enhanced antibody production associated with the BCG/SCV2 combination strategy.
